Wells Fargo & Company Increases Mesa Laboratories (NASDAQ:MLAB) Price Target to $110.00

Mesa Laboratories (NASDAQ:MLAB) had its target price boosted by equities research analysts at Wells Fargo & Company from $94.00 to $110.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target suggests a potential downside of 1.82% from the stock’s current price.

Separately, Weiss Ratings upgraded Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research note on Tuesday. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $110.00.

Mesa Laboratories Stock Down 1.0%

MLAB stock traded down $1.16 during trading on Friday, hitting $112.04. 48,149 shares of the stock traded hands, compared to its average volume of 147,655. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The stock has a market cap of $626.97 million, a price-to-earnings ratio of 133.36 and a beta of 0.92. Mesa Laboratories has a 1 year low of $58.83 and a 1 year high of $115.52. The firm’s 50 day moving average is $100.59 and its two-hundred day moving average is $95.90.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The company had revenue of $60.14 million during the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.87%.

Insider Transactions at Mesa Laboratories

In related news, CFO John Sakys sold 2,827 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $253,016.50. Following the transaction, the chief financial officer owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the sale, the senior vice president owned 6,377 shares of the company’s stock, valued at $570,741.50. The trade was a 28.29% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 8,277 shares of company stock worth $770,122. 2.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mesa Laboratories

A number of institutional investors have recently added to or reduced their stakes in MLAB. Northwestern Mutual Wealth Management Co. raised its stake in shares of Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Mesa Laboratories in the fourth quarter worth $27,000. Kestra Advisory Services LLC purchased a new stake in Mesa Laboratories in the fourth quarter valued at approximately $55,000. BNP Paribas Financial Markets raised its position in Mesa Laboratories by 115.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 421 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after acquiring an additional 684 shares during the period. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.